Abstract
Background/objectives
Generic competition has markedly reduced the cost of medications for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), potentially reshaping the value proposition of first-line therapy. We reviewed contemporary drug pricing and health-economic evidence to evaluate the cost-effectiveness of medical therapy as initial management for BPH/LUTS.
Subjects/methods
We synthesized evidence from randomized trials, meta-analyses, international guidelines, and published cost-effectiveness/cost-utility analyses comparing pharmacotherapy with common minimally invasive and surgical BPH interventions.
Results
Common generic agents (e.g., tamsulosin and finasteride) are available for approximately $2–$7 per month through discount programs. Clinical trial evidence demonstrates meaningful symptom improvement and reduced risk of progression with alpha-blockers and 5-alpha-reductase inhibitors, particularly in combination therapy. Published economic models consistently show favorable incremental cost-effectiveness ratios for medical management versus watchful waiting or surgery; under current generic pricing, medication costs rarely approach the one-time costs of procedural interventions within a typical lifespan.
Conclusions
Contemporary clinical and economic evidence supports medical therapy as a highly cost-effective first-line treatment for BPH/LUTS, with procedural interventions best reserved for medication failure, complications, or patient preference.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Haile ES, Sotimehin AE, Gill BC. Medical management of benign prostatic hyperplasia. Cleve Clin J Med. 2024;91:163–70. https://doi.org/10.3949/ccjm.91a.23027.
Impax Laboratories, Inc. Impax Laboratories receives final FDA approval for generic Flomax 0.4 mg capsules and immediately commences shipment [press release]. 2010.
Sandhu JS, Bixler BR, Dahm P, Das AK, Gandhi MC, Kaplan SA, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2023;210:1116–26. https://doi.org/10.1097/JU.0000000000003698.
Gravas S, Gacci M, Gratzke C, Herrmann T, Karavitakis M, Kyriazis I, et al. Summary of the 2023 European Association of Urology Guidelines on the Management of Male Lower Urinary Tract Symptoms. Eur Urol. 2023;84:207–22. https://doi.org/10.1016/j.eururo.2023.04.008.
McConnell JD, Roehrborn CG, Bautista O, Andriole GL Jr, Dixon CM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med. 2003;349:2387–98. https://doi.org/10.1056/NEJMoa030656.
Isharwal S, Johanning JM, Dwyer JG, Schiffman MH, Berger PB. Cost-effectiveness of fixed-dose combination of dutasteride and tamsulosin (Duodart) compared with dutasteride monotherapy in patients with benign prostatic hyperplasia: a Canadian perspective. Can Urol Assoc J. 2013;7:E682–90. https://doi.org/10.5489/cuaj.1893.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year results from the CombAT study. Eur Urol. 2010;57:123–31. https://doi.org/10.1016/j.eururo.2009.09.035.
Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the CombAT trial. BJU Int. 2012;109:731–8. https://doi.org/10.1111/j.1464-410X.2011.10521.x.
Yoosuf BT, Panda A, Bharti MK, Devana SK, Bansal SK. D. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep. 2024;14:11116. https://doi.org/10.1038/s41598-024-61977-5.
Eure G, Rukstalis D, Lee R, Concepcion RS, Ukani M. Cost-effectiveness comparison of prostatic urethral lift versus medical management and transurethral resection of the prostate for moderate-to-severe BPH. Urol Pract. 2021;8:487–92. https://doi.org/10.1097/UPJ.0000000000000229.
McVary KT, Roehrborn CG. Five-year results of the prospective, randomized controlled trial of water vapor thermal therapy for BPH. J Urol. 2021;206:715–24. https://doi.org/10.1097/JU.0000000000001778.
Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five-year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802–13.
Bagla S, Smirniotopoulos J, Orlando JC, Piechowiak R. Cost analysis of prostate artery embolization (PAE) and transurethral resection of the prostate (TURP) in the treatment of benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2017;40:1694–7. https://doi.org/10.1007/s00270-017-1700-7.
Müllhaupt G, Hechelhammer L, Engeler DS, Gusewell S, Mordasini L, Schmid HP, Abt D. In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. BJU Int. 2019;123:1055–60. https://doi.org/10.1111/bju.14667.
Modi S, Ahmed K, Abboudi H, Vigneswaran G, de Preux L, Maclean D, et al. One-year cost-utility analysis of prostate artery embolization versus transurethral resection of the prostate in benign prostatic hyperplasia. BMJ Surg Interv Health Technol. 2021;3:e000071. https://doi.org/10.1136/bmjsit-2020-000071.
Sapoval M, Thiounn N, Descazeaud A, Déan C, Ruffion A, de la Taille A, et al. Prostatic artery embolisation versus medical treatment in patients with BPH (PARTEM): a randomised, multicentre, open-label phase 3 trial. Lancet Reg Health Eur. 2023;31:100672. https://doi.org/10.1016/j.lanepe.2023.100672.
Johnston KM, Gupte-Singh K, Erickson K, Mason-Lai P, McVary KT. A cost-effectiveness analysis evaluating water vapor thermal therapy for benign prostatic hyperplasia. Curr Med Res Opin. 2022;38:1089–97. https://doi.org/10.1080/03007995.2022.2057155.
Kaufman RP Jr, Bagley DH, Krane RJ, Whitmore KE, Kogan BA, Hanno PM, et al. Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study. Prostate Cancer Prostatic Dis. 2024;27:138–47. https://doi.org/10.1038/s41391-023-00741-8.
Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E, Pisco JM, et al. Long-term outcome of prostatic artery embolization for patients with BPH: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol. 2022;45:1324–36. https://doi.org/10.1007/s00270-022-03199-8.
Abt D, Hechelhammer L, Müllhaupt G, Markart S, Güsewell S, Schmid HP, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-year outcomes of a randomized, open-label, single-centre trial. Eur Urol. 2021;80:34–42. https://doi.org/10.1016/j.eururo.2021.02.008.
Author information
Authors and Affiliations
Contributions
A.E.T. and S.A.K. conceived the work. A.R. and A.E.T. performed the literature review and drafted the manuscript. A.E.T. and S.A.K. critically revised the manuscript for important intellectual content. All authors approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All methods were performed in accordance with relevant guidelines and regulations. This article is a narrative review and analysis of published literature and publicly available information and did not involve new studies of human participants or animals; therefore approval from an ethics committee and informed consent to participate were not required. No identifiable human images are included; consent for publication was not applicable.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Te, A.E., Ramaswamy, A. & Kaplan, S.A. Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS. Prostate Cancer Prostatic Dis (2026). https://doi.org/10.1038/s41391-026-01089-5
Received:
Revised:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1038/s41391-026-01089-5
